Q-omics provides the consensus-scored PGAM1P11 profile across patient tissues and cancer cell-line models. PGAM1P11 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PGAM1P11 is differentially expressed in 7, with the highest sampling consensus in BLCA. Additionally, PGAM1P11 RNA expression shows 11,855 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where PGAM1P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGAM1P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGAM1P11 survival associations across molecular data types. PGAM1P11 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGAM1P11 RNA expression–survival associations across cancer types. High PGAM1P11 expression shows unfavorable associations in ACC, THYM and COAD, but favorable associations in KIRP, HNSC and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PGAM1P11 RNA expression.
This table summarizes PGAM1P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PGAM1P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGAM1P11 shows higher tumor expression in BLCA, STAD, COAD, LIHC, HNSC and CHOL. The BLCA box plot shows higher PGAM1P11 RNA expression in tumor versus normal tissue (log2 FC = +0.257, t-test p < 0.001).
This table shows molecular features associated with PGAM1P11 in patient tissues and cancer cell lines. In patient samples, PGAM1P11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
